Association of TP53codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients
Open Access
- 30 May 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 9 (3), R34
- https://doi.org/10.1186/bcr1682
Abstract
Single-nucleotide polymorphisms (SNPs) in codon 72 of the TP53 (also known as p53) gene (rs1042522) and in the promoter region of the MDM2 gene (SNP309; rs2279744) have been suggested to play roles in many cancers. We investigated whether these SNPs were associated with patient outcome and the effect of adjuvant systemic therapy. The genotypes of TP53 codon 72 and MDM2 SNP309 were defined among 557 primary Japanese breast cancer patients (median follow-up, 61.7 months). The effects of several variables on survival were tested by Cox's proportional hazards regression analysis. We showed that the Pro/Pro genotype of TP53 codon 72 was associated with poorer disease-free survival (DFS) than other genotypes by Kaplan-Meier analysis (P = 0.049) and multivariate Cox's proportional hazards regression analysis (P = 0.047, risk ratio of recurrence = 1.67), whereas MDM2 SNP309 status was not associated with DFS. The association of the Pro/Pro TP53 genotype with poorer DFS was especially significant in patients who received adjuvant chemotherapy (P = 0.009). In contrast, among the patients who had received adjuvant hormonal therapy or no adjuvant systemic therapy, TP53 codon 72 genotype was not associated with DFS. The Pro/Pro genotype of TP53 codon 72 appears to be an independent prognostic marker in breast cancer patients.Keywords
This publication has 43 references indexed in Scilit:
- Commonly Studied Single-Nucleotide Polymorphisms and Breast Cancer: Results From the Breast Cancer Association ConsortiumJNCI Journal of the National Cancer Institute, 2006
- p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patientsPharmacogenetics and Genomics, 2006
- The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.Clinical Cancer Research, 2006
- TP53 and P21 polymorphisms: Response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancerBiochemical and Biophysical Research Communications, 2006
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- The codon 72 polymorphic variants of p53 have markedly different apoptotic potentialNature Genetics, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Abnormal expression of MDM-2 in breast carcinomasBreast Cancer Research and Treatment, 1996
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991